Abstract
Similar to other pathogens, HIV can directly activate the complement pathway even in the absence of antibodies. During and after seroconversion, HIV-specific antibodies enhance the activation of complement and increase deposition of complement fragments on virions dramatically. However, even in the presence of HIV-specific antibodies, no or only poor lysis occurs. HIV has adapted different protection mechanisms to keep complement activation under the threshold necessary to induce virolysis. In addition to its own envelope proteins, the viral envelope contains membrane-anchored host molecules. Among those are complement regulatory proteins that remain functionally active on the surface of HIV and turn down the complement cascade. In addition, serum proteins with complement regulatory activities become secondarily attached onto the virus, thereby enhancing the protection of HIV against complement-mediated damage. Therefore, opsonised virions accumulate in HIV-infected individuals, which subsequently interact with complement receptor (CR) expressing cells. This review is mainly focused on these interactions, which result either in infection of CR-positive cells with high efficiency, or retention of viral particles on their surface via CRs, thereby promoting transmission of virus to other permissive cells.
Keywords: HIV Infection, Cell Perturbations, C5a Receptor
Current Molecular Medicine
Title: Complement Receptors in HIV Infection
Volume: 2 Issue: 8
Author(s): S. Doepper, L. Kacani, B. Falkensammer, M. P. Dierich and H. Stoiber
Affiliation:
Keywords: HIV Infection, Cell Perturbations, C5a Receptor
Abstract: Similar to other pathogens, HIV can directly activate the complement pathway even in the absence of antibodies. During and after seroconversion, HIV-specific antibodies enhance the activation of complement and increase deposition of complement fragments on virions dramatically. However, even in the presence of HIV-specific antibodies, no or only poor lysis occurs. HIV has adapted different protection mechanisms to keep complement activation under the threshold necessary to induce virolysis. In addition to its own envelope proteins, the viral envelope contains membrane-anchored host molecules. Among those are complement regulatory proteins that remain functionally active on the surface of HIV and turn down the complement cascade. In addition, serum proteins with complement regulatory activities become secondarily attached onto the virus, thereby enhancing the protection of HIV against complement-mediated damage. Therefore, opsonised virions accumulate in HIV-infected individuals, which subsequently interact with complement receptor (CR) expressing cells. This review is mainly focused on these interactions, which result either in infection of CR-positive cells with high efficiency, or retention of viral particles on their surface via CRs, thereby promoting transmission of virus to other permissive cells.
Export Options
About this article
Cite this article as:
Doepper S., Kacani L., Falkensammer B., Dierich P. M. and Stoiber H., Complement Receptors in HIV Infection, Current Molecular Medicine 2002; 2 (8) . https://dx.doi.org/10.2174/1566524023361826
DOI https://dx.doi.org/10.2174/1566524023361826 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Body Mass Index (BMI) and Cognitive Functions in Later Life
Current Alzheimer Research Aging Successfully: The Role of Genetics and Environment in the Era of the Aging-Boom. Potential Therapeutic Implications
Current Pharmaceutical Design Inhibitors of Leucine-Rich Repeat Kinase 2 (LRRK2): Progress and Promise for the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders
Current Molecular Medicine Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections
Current Pharmaceutical Design Synaptic Plasticity, Metaplasticity and Depression
Current Neuropharmacology Hepatic Encephalopathy: Cause and Possible Management with Botanicals
Recent Patents on Inflammation & Allergy Drug Discovery Partners in Crime: NGF and BDNF in Visceral Dysfunction
Current Neuropharmacology Testosterone Replacement Therapy in Older Male Subjective Memory Complainers: Double-Blind Randomized Crossover Placebo-Controlled Clinical Trial of Physiological Assessment and Safety
CNS & Neurological Disorders - Drug Targets MicroRNAs for the Treatment of Dementia and Alzheimer’s Disease
Current Neurovascular Research Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs
Current Topics in Medicinal Chemistry Roles of Casein Kinase I η and δ in Gastrointestinal Cancers: Potential New Screening Markers and Drug Targets
Current Cancer Therapy Reviews Cardiovascular and Renovascular Implications of COX-2 Inhibition
Current Pharmaceutical Design Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Current Neuropharmacology Pathological Gambling in Parkinson’s Disease: An Update on Medical Management
Current Psychopharmacology The Multidisciplinary Issue of Obesity: Epidemiological Studies, Company Strategies and Policy Actions: A Systematic and Methodological Review of the Research Approaches
Recent Patents on Food, Nutrition & Agriculture Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence
Current Drug Metabolism Effect of Nicotine on ATPase, Catalase and Calcium Levels in the Presence of Oligoelements in Brain Regions of Young Rats
Cardiovascular & Hematological Disorders-Drug Targets Why Some Messages Speak Better: Child Immunization in the News and on the Internet
Current Drug Safety